Medical device company ICU Medical (NASDAQ:ICUI) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 7.1% year on year to $629.8 million. Its non-GAAP profit of $2.11 per share was 42.4% above analysts’ consensus estimates.
Behavioral health company Acadia Healthcare (NASDAQ:ACHC) missed Wall Street’s revenue expectations in Q4 CY2024 as sales rose 4.2% year on year to $774.2 million. Next quarter’s revenue guidance of $770 million underwhelmed, coming in 5.8% below analysts’ estimates. Its non-GAAP profit of $0.64 per share was 10.4% below analysts’ consensus estimates.
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) missed Wall Street’s revenue expectations in Q4 CY2024 as sales rose 4.7% year on year to $186.5 million. Its non-GAAP profit of $0.92 per share was 1.9% below analysts’ consensus estimates.
Health insurance company Clover Health (NASDAQ:CLOV) missed Wall Street’s revenue expectations in Q4 CY2024, with sales falling 34% year on year to $337 million. Its GAAP loss of $0.04 per share was $0.03 above analysts’ consensus estimates.
Global media and entertainment company iHeartMedia (NASDAQ:IHRT) missed Wall Street’s revenue expectations in Q4 CY2024 as sales rose 4.8% year on year to $1.12 billion. On the other hand, next quarter’s outlook exceeded expectations with revenue guided to $1.10 billion at the midpoint, or 33.7% above analysts’ estimates.
Healthcare services company Astrana Health announced better-than-expected revenue in Q4 CY2024, with sales up 88.4% year on year to $665.2 million. The company expects the full year’s revenue to be around $2.6 billion, close to analysts’ estimates. Its GAAP loss of $0.15 per share was significantly below analysts’ consensus estimates.
Energy drink company Monster Beverage (NASDAQ:MNST) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 4.7% year on year to $1.81 billion. Its non-GAAP profit of $0.38 per share was 5.5% below analysts’ consensus estimates.
Genetic testing company Natera (NASDAQ:NTRA). reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 53% year on year to $476.1 million. The company’s full-year revenue guidance of $1.91 billion at the midpoint came in 5.8% above analysts’ estimates. Its GAAP loss of $0.41 per share was 9.3% below analysts’ consensus estimates.
(Bloomberg) -- For two years, Wall Street traders have minted profits simply by chasing the hottest stocks in the market regardless of price, fundamentals or the economic backdrop. Those days appear to be over.Most Read from BloombergCuts to Section 8 Housing Assistance Loom Amid HUD UncertaintyThe Trump Administration Takes Aim at Transportation ResearchShelters Await Billions in Federal Money for Homelessness ProvidersNYC’s Congestion Pricing Pulls In $48.6 Million in First MonthNew York’s Con
Voice AI recognition company SoundHound (NASDAQ:SOUN) announced better-than-expected revenue in Q4 CY2024, with sales up 101% year on year to $34.54 million. Its GAAP loss of $0.69 per share was significantly below analysts’ consensus estimates.